Trial Profile
A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs AUTO-4 (Primary)
- Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms LibrA T1
- Sponsors Autolus
- 21 Mar 2024 This study has been Discontinued in Spain, according to European Clinical Trials Database record.
- 01 Jul 2023 This study has been suspended in Spain, According to European Clinical Trials Database.
- 13 Dec 2022 Results (n=73)presented at the 64th American Society of Hematology Annual Meeting and Exposition